stockrow
Saturday 7 November 2026
Export PMN’s income statement to Excel — free account
Promis Neurosciences
- EPS
- +82.3%
- Free cash flow
- −169.5%
Quarter to June 2026, against a year earlier
4.07
0.42
+11.51%
Follow PMN
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | 0 | 0 | 0 | 0 | 0 | — | — | — | — | — | 0 | (10.2%) | 3 | 3 | 3 | 0.0% | |
| Gross margin, % | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 0.00 | 0.00 | — | — | — | 0.00 | (100.0) pt | ||||||
| EBT | (3) | (5) | (8) | (6) | (4) | (10) | (18) | (13) | 3 | (40) | (42) | +35.3% | ||||||
| EBT margin, % | (130,460.00) | (61,102.63) | (1,960,975.00) | (619,311.11) | (325,153.85) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | +130,460.0 pt | ||||||
| Net income | (3) | (5) | (8) | (6) | (4) | (10) | (18) | (13) | 3 | (40) | (42) | +35.3% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.02 | 0.06 | 0.00 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | (22.99) | (33.77) | (44.91) | (29.94) | (22.16) | (42.30) | (60.25) | (26.75) | 2.75 | (22.61) | (13.21) | (0.2%) | ||||||
| Cash flow | (16.93) | (31.97) | (41.73) | (26.45) | (17.04) | (40.21) | (56.76) | (22.05) | (26.21) | (16.00) | (4.61) | (0.6%) | ||||||
| Capex | 0.00 | 0.00 | 0.00 | 0.00 | (0.43) | 0.40 | (0.01) | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | (16.93) | (31.97) | (41.73) | (26.45) | (17.46) | (39.81) | (56.77) | (22.05) | (26.21) | (16.00) | (4.61) | (0.6%) | ||||||
| Book value | 0.46 | 8.60 | 5.58 | 1.73 | (3.97) | 24.46 | (4.49) | 7.63 | 15.90 | (0.72) | 5.40 | n/m | ||||||
| Shares, m | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 5 | +35.6% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | 0.00 | 0.0 | |||||
| P/S | 0.00 | 0.00 | 6,272.99 | 31,460.28 | 10,782.80 | — | — | — | — | — | 16,913.44 | 9,703.2 | ||||||
| P/B | 0.00 | 28.24 | 53.44 | 115.35 | 0.00 | — | — | — | — | — | 0.75 | 39.4 | ||||||
| EV/Sales | 0.00 | 0.00 | 6,026.19 | 30,293.19 | 10,419.39 | — | — | — | — | — | (5,572.97) | 9,347.8 | ||||||
| EV/FCF | 0.00 | (7.29) | (6.87) | (7.26) | (7.05) | — | — | — | — | — | 0.29 | (5.7) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (2) | (4) | (7) | (5) | (3) | (9) | (17) | (11) | (27) | (28) | (42) | +34.7% | |||||
| Capex | — | — | — | — | 0 | 0 | 0 | — | — | — | 0 | (84.3%) | ||||||
| Free cash flow | (2) | (4) | (7) | (5) | (3) | (9) | (17) | (11) | (27) | (28) | (42) | +34.7% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 0 | 1 | 1 | 0 | (1) | 17 | 0 | 4 | 17 | (1) | 49 | +133.3% | |||||
| Net debt | (1) | (1) | (2) | (1) | (1) | (13) | (6) | (13) | (13) | (6) | (53) | +30.3% | ||||||
| Shareholders’ equity | 0 | 1 | 1 | 0 | (1) | 6 | (1) | 4 | 16 | (1) | 49 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | 0.00 | (386.10) | (395.87) | (289.47) | (325.59) | (104.26) | (146.42) | (128.63) | 17.08 | (282.76) | (127.57) | (282.8) pt | |||||
| ROIC | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (332.40) | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | 0.00 | (751.91) | (756.07) | (935.12) | 1,844.24 | (399.46) | (837.71) | (1,098.52) | 27.46 | (521.61) | (172.30) | (521.6) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | 7 | 7 | 8 | 11 | — | +16.3% | |||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2020 · latest quarter Dec 2020 · fundamentals updated 26 Oct 2026
Promis Neurosciences vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| PTHS Pelthos Therapeutics Inc. | $35.6M | — (loss-making) | — (loss-making) | — | n/m | −1,614.99% (below 0%: shrinking) | 76.86% | (111.02%) | Compare |
| VERU Veru Inc. | $35.1M | — (loss-making) | — (loss-making) | +99.23% (above 0%: growing) | n/m | +0.27% (above 0%: growing) | 67.84% | 0.00% | Compare |
| LIANY LianBio Sponsored ADR | $34.2M | 0.0× | — | — | n/m | +1,107.59% (above 0%: growing) | 0.00% | 0.00% | Compare |
| GRDX GridAI Technologies Corp. | $33.3M | — (loss-making) | — | — | n/m | −2,640.98% (below 0%: shrinking) | (42.49%) | (15,258.21%) | Compare |
| NNVC NanoViricides, Inc. | $32.9M | — (loss-making) | — | — | n/m | −23.94% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| PMN Promis Neurosciences | $32.7M | — (loss-making) | — | 0.00% | n/m | −169.46% (below 0%: shrinking) | 0.00% | 0.00% | |
| INMB INmune Bio, Inc. | $32.6M | — (loss-making) | — (loss-making) | +8.70% (above 0%: growing) | n/m | +55.39% (above 0%: growing) | 100.00% | 0.00% | Compare |
| EYPT EyePoint, Inc. | $30.7M | — (loss-making) | — (loss-making) | −90.49% (below 0%: shrinking) | n/m | +0.41% (above 0%: growing) | 100.00% | (19,207.10%) | Compare |
| IRLA IRulya Therapeutics Inc. | $29.8M | — (loss-making) | — | — | n/m | −63.65% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $33.1M | — | — | +8.70% | — | −11.83% | 33.92% | 0.00% |